Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with ...
Tonix Pharmaceuticals (TNXP) announced plans to progress its TNX-2900 program for the treatment of Prader-Willi syndrome into a Phase 2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback